If you are interested in using AI to search information, I found...

If you are interested in using AI to search information, I found Grok is probably a good one to try,
here's an exercise for the list of M&A activities generated by Grok:

"
M&A Involving Rare Disease Pharma Companies (2022–2025)

1. 1. Amgen Acquires Horizon Therapeutics
      • • Date: Completed December 2023
      • • Value: $27.8 billion
      • • Details: Amgen acquired Horizon, a company specializing in rare autoimmune and inflammatory diseases. Horizon’s portfolio includes Tepezza (for thyroid eye disease) and Krystexxa (for chronic refractory gout), both targeting rare conditions with limited treatment options. Like Neuren, Horizon focuses on niche, high-unmet-need markets.
      • • Similarity: Rare disease focus, premium valuation for specialized therapies.

1. 1. Pfizer Acquires Biohaven Pharmaceuticals
      • • Date: Completed October 2022
      • • Value: $11.6 billion
      • • Details: Biohaven developed treatments for neurological disorders, including Nurtec ODT for migraine and a pipeline for rare diseases like spinocerebellar ataxia. Pfizer retained Biohaven’s non-rare disease assets, while the rare disease pipeline spun out into a new entity.
      • • Similarity: Neurological focus, clinical-stage assets targeting rare conditions.

1. 1. Merck & Co. Acquires Prometheus Biosciences
      • • Date: Completed June 2023
      • • Value: $10.8 billion
      • • Details: Prometheus focused on rare autoimmune diseases, particularly inflammatory bowel diseases like Crohn’s and ulcerative colitis, with its lead candidate MK-7240. Its precision medicine approach aligns with rare disease innovation.
      • • Similarity: Rare disease therapies, significant milestone potential.

1. 1. Biogen Acquires Reata Pharmaceuticals
      • • Date: Completed September 2023
      • • Value: $7.3 billion
      • • Details: Reata developed therapies for rare neurological diseases, including Skyclarys, the first FDA-approved treatment for Friedreich’s ataxia, a progressive genetic disorder.
      • • Similarity: Rare neurological focus, orphan drug designation, pediatric potential.

1. 1. AstraZeneca Acquires Alexion Pharmaceuticals
      • • Date: Completed July 2021 (just outside the three-year window but notable)**
      • • Value: $39 billion
      • • Details: Alexion specialized in rare diseases, including neurological conditions like generalized myasthenia gravis and paroxysmal nocturnal hemoglobinuria. Given its prominence, it’s included as a benchmark.
      • • Similarity: Rare disease leadership, neurological overlap.

1. 1. AstraZeneca Acquires Amolyt Pharma
      • • Date: Announced March 2024, completed later in 2024
      • • Value: $1.05 billion
      • • Details: Amolyt focused on rare endocrine disorders, with a lead candidate for hypoparathyroidism. Its small size and clinical-stage status mirror Neuren’s profile.
      • • Similarity: Rare disease, clinical-stage, niche therapeutic area.

1. 1. Eli Lilly Acquires Morphic Holding
      • • Date: Completed August 2024
      • • Value: $3.2 billion
      • • Details: Morphic developed oral integrin therapies for chronic diseases, including a candidate MORF-057 for rare inflammatory conditions like IBD.
      • • Similarity: Rare disease pipeline, innovative therapy development.

1. 1. Lundbeck Acquires Longboard Pharmaceuticals
      • • Date: Announced October 2024, pending closure as of February 2025
      • • Value: $2.6 billion
      • • Details: Longboard focused on rare neurological conditions, with a lead candidate for developmental and epileptic encephalopathies, rare seizure disorders emerging in childhood.
      • • Similarity: Rare neurodevelopmental focus, early childhood disorders.

Notes on Neuren-Specific Context

• • Neuren itself has not been acquired but expanded its partnership with Acadia Pharmaceuticals in 2023, receiving $155 million upfront and potential milestones up to $1.2 billion for trofinetide (DAYBUE) and NNZ-2591. This deal reflects a strategic collaboration rather than an outright acquisition, common among rare disease firms leveraging larger partners.

• • Most M&A activity in this space involves larger pharma acquiring smaller, clinical-stage companies with promising rare disease pipelines, a pattern Neuren could fit into if acquired.

Observations

• • Trend: Large pharma companies (e.g., Pfizer, Amgen, Merck) dominate acquisitions, targeting rare disease firms to bolster pipelines amid declining revenues from blockbuster drugs.

• • Valuation: Deals range from $1 billion to over $27 billion, reflecting high premiums for rare disease assets with regulatory approvals or strong clinical data.

• • Focus Areas: Neurological, genetic, and autoimmune rare diseases are hotspots, aligning with Neuren’s neurodevelopmental niche.

This list captures significant M&A activity similar to Neuren’s profile."

Just food for thoughts.

DYOR.